BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37529049)

  • 1. A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy.
    Liu D; Wang J; You W; Ma F; Sun Q; She J; He W; Yang G
    Front Immunol; 2023; 14():1228581. PubMed ID: 37529049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
    Guo L; Overholser J; Darby H; Ede NJ; Kaumaya PTP
    Oncoimmunology; 2022; 11(1):2127691. PubMed ID: 36211807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.
    Lai X; Yao F; An Y; Li X; Yang XD
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
    Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
    Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy.
    Liang Y; Luo H; Li X; Liu S; Habib A; Liu B; Huang J; Wang J; Yi H; Hu B; Zheng L; Xie J; Zhu N
    Front Immunol; 2024; 15():1367040. PubMed ID: 38745661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
    Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
    Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 8. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy.
    Zeng W; Pan J; Fang Z; Jia J; Zhang R; He M; Zhong H; He J; Yang X; Shi Y; Zhong B; Zeng J; Fu B; Huang M; Liu H
    Front Immunol; 2022; 13():925217. PubMed ID: 35795680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy.
    Jiao L; Dong Q; Zhai W; Zhao W; Shi P; Wu Y; Zhou X; Gao Y
    Pharmacol Res; 2022 Aug; 182():106343. PubMed ID: 35798286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
    Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
    J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction.
    Overholser J; Guo L; Kaumaya PTP
    J Vis Exp; 2023 Jul; (197):. PubMed ID: 37486131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
    Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
    Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with 17β-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model.
    Song CH; Kim N; Nam RH; Choi SI; Jang JY; Kim JW; Na HY; Lee HN
    Cancer Lett; 2022 Sep; 543():215780. PubMed ID: 35690286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fish oil-based microemulsion can efficiently deliver oral peptide blocking PD-1/PD-L1 and simultaneously induce ferroptosis for cancer immunotherapy.
    Yang X; Li W; Li S; Chen S; Hu Z; He Z; Zhu X; Niu X; Zhou X; Li H; Xiao Y; Liu J; Sui X; Chen G; Gao Y
    J Control Release; 2024 Jan; 365():654-667. PubMed ID: 38030081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.